MannKind grants Tolero Pharmaceuticals rights to its BTK program for cancer and inflammation
MannKind Corp. (therapeutics for diabetes and cancer) has granted start-up Tolero Pharmaceuticals Inc. (drug discovery based on genetic pathway abnormalities) exclusive worldwide rights to its Bruton’s tyrosine kinase (BTK) program, which is in preclinical studies for blood cancers and inflammatory diseases.
Drug Discovery Tools
- Drug Discovery Tools
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.